tiprankstipranks
Advertisement
Advertisement
Teva says biosimilars a growth pipeline for the company
PremiumThe FlyTeva says biosimilars a growth pipeline for the company
16d ago
Teva reports Q2 EPS 2c, consensus 11c
Premium
The Fly
Teva reports Q2 EPS 2c, consensus 11c
16d ago
Teva backs FY26 EPS view $1.91-$2.11, consensus $2.16
Premium
The Fly
Teva backs FY26 EPS view $1.91-$2.11, consensus $2.16
16d ago
Teva, Polpharma enter global licensing agreement for Ocrevus biosimilar
PremiumThe FlyTeva, Polpharma enter global licensing agreement for Ocrevus biosimilar
1M ago
Teva, Polpharma Biologics announce global licensing agreement
Premium
The Fly
Teva, Polpharma Biologics announce global licensing agreement
1M ago
Teva, Samsung Bioepis enter commercialization agreement for OPUVIZ
Premium
The Fly
Teva, Samsung Bioepis enter commercialization agreement for OPUVIZ
1M ago
Teva submits NDA for Ecopipam to FDA
PremiumThe FlyTeva submits NDA for Ecopipam to FDA
2M ago
Jefferies continues to like Teva after recent pullback
Premium
The Fly
Jefferies continues to like Teva after recent pullback
2M ago
Teva put volume heavy and directionally bearish
Premium
The Fly
Teva put volume heavy and directionally bearish
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100